SCI REP:甲状腺乳头状癌患者BRAF V600E突变和超声特征之间的关联!

2017-07-08 xing.T MedSci原创

总之,老龄和微钙化是甲状腺乳头状癌患者BRAF突变的危险因素,尤其是在那些没有HT的患者中。对于那些有HT的患者,有BRAF突变的PTCs往往在超声上表现为实体。在制定治疗计划或预后评估时,可能需要考虑这些因素。

近日,Scientific reports 杂志上发表了一篇研究文章,研究人员的目的是评估BRAF V600E突变和有和无Hashimoto甲状腺炎(HT)甲状腺乳头状癌(PTC)的超声特征之间的相关性。

研究人员回顾性地分析了连续就诊的438例手术证实PTCs患者的超声特点和BRAF V600E突变状态。研究人员分析了BRAF基因突变与超声特征之间的关系。此外,研究人员还对共存的HT进行了亚组分析。

研究人员发现86.5%的患者存在BRAF突变(379/438)。患者年龄(比值比为1.028,P=0.010),年龄≥50岁(比值比为1.904,P=0.030)和超声上微钙化(比值比为2.262,P=0.015)与PTC患者BRAF突变显著相关。超声上实体成分(比值比为5.739,P=0.019)是HT患者BRAF突变的重要预测因素,而年龄(比值比为1.036,P=0.017)和微钙化(比值比为3.093,P=0.017)与无HT患者的BRAF突变显著相关。

总之,老龄和微钙化是甲状腺乳头状癌患者BRAF突变的危险因素,尤其是在那些没有HT的患者中。对于那些有HT的患者,有BRAF突变的PTCs往往在超声上表现为实体。在制定治疗计划或预后评估时,可能需要考虑这些因素。

原始出处:

Qin Zhang,et al. Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto’s Thyroiditis.Scientific reports. 2017. https://www.nature.com/articles/s41598-017-05153-y

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086217, encodeId=d714208621ef0, content=<a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18243, encryptionId=ed621824388, topicName=V600E突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 04 11:55:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798694, encodeId=1e241e986944a, content=<a href='/topic/show?id=4f6c698486b' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69848, encryptionId=4f6c698486b, topicName=甲状腺乳头状癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 27 21:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813496, encodeId=7f1b181349689, content=<a href='/topic/show?id=b887928146b' target=_blank style='color:#2F92EE;'>#超声特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92814, encryptionId=b887928146b, topicName=超声特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Aug 07 02:55:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044979, encodeId=924120449e925, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 25 08:55:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354964, encodeId=188f1354964a3, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363792, encodeId=02921363e92b6, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220474, encodeId=fbdf2204e435, content=谢谢分享,有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Mon Jul 10 00:50:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219946, encodeId=06a121994660, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jul 08 12:54:18 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086217, encodeId=d714208621ef0, content=<a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18243, encryptionId=ed621824388, topicName=V600E突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 04 11:55:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798694, encodeId=1e241e986944a, content=<a href='/topic/show?id=4f6c698486b' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69848, encryptionId=4f6c698486b, topicName=甲状腺乳头状癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 27 21:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813496, encodeId=7f1b181349689, content=<a href='/topic/show?id=b887928146b' target=_blank style='color:#2F92EE;'>#超声特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92814, encryptionId=b887928146b, topicName=超声特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Aug 07 02:55:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044979, encodeId=924120449e925, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 25 08:55:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354964, encodeId=188f1354964a3, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363792, encodeId=02921363e92b6, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220474, encodeId=fbdf2204e435, content=谢谢分享,有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Mon Jul 10 00:50:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219946, encodeId=06a121994660, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jul 08 12:54:18 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086217, encodeId=d714208621ef0, content=<a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18243, encryptionId=ed621824388, topicName=V600E突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 04 11:55:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798694, encodeId=1e241e986944a, content=<a href='/topic/show?id=4f6c698486b' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69848, encryptionId=4f6c698486b, topicName=甲状腺乳头状癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 27 21:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813496, encodeId=7f1b181349689, content=<a href='/topic/show?id=b887928146b' target=_blank style='color:#2F92EE;'>#超声特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92814, encryptionId=b887928146b, topicName=超声特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Aug 07 02:55:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044979, encodeId=924120449e925, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 25 08:55:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354964, encodeId=188f1354964a3, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363792, encodeId=02921363e92b6, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220474, encodeId=fbdf2204e435, content=谢谢分享,有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Mon Jul 10 00:50:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219946, encodeId=06a121994660, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jul 08 12:54:18 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086217, encodeId=d714208621ef0, content=<a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18243, encryptionId=ed621824388, topicName=V600E突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 04 11:55:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798694, encodeId=1e241e986944a, content=<a href='/topic/show?id=4f6c698486b' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69848, encryptionId=4f6c698486b, topicName=甲状腺乳头状癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 27 21:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813496, encodeId=7f1b181349689, content=<a href='/topic/show?id=b887928146b' target=_blank style='color:#2F92EE;'>#超声特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92814, encryptionId=b887928146b, topicName=超声特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Aug 07 02:55:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044979, encodeId=924120449e925, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 25 08:55:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354964, encodeId=188f1354964a3, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363792, encodeId=02921363e92b6, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220474, encodeId=fbdf2204e435, content=谢谢分享,有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Mon Jul 10 00:50:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219946, encodeId=06a121994660, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jul 08 12:54:18 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086217, encodeId=d714208621ef0, content=<a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18243, encryptionId=ed621824388, topicName=V600E突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 04 11:55:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798694, encodeId=1e241e986944a, content=<a href='/topic/show?id=4f6c698486b' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69848, encryptionId=4f6c698486b, topicName=甲状腺乳头状癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 27 21:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813496, encodeId=7f1b181349689, content=<a href='/topic/show?id=b887928146b' target=_blank style='color:#2F92EE;'>#超声特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92814, encryptionId=b887928146b, topicName=超声特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Aug 07 02:55:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044979, encodeId=924120449e925, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 25 08:55:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354964, encodeId=188f1354964a3, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363792, encodeId=02921363e92b6, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220474, encodeId=fbdf2204e435, content=谢谢分享,有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Mon Jul 10 00:50:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219946, encodeId=06a121994660, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jul 08 12:54:18 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
    2017-07-10 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=2086217, encodeId=d714208621ef0, content=<a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18243, encryptionId=ed621824388, topicName=V600E突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 04 11:55:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798694, encodeId=1e241e986944a, content=<a href='/topic/show?id=4f6c698486b' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69848, encryptionId=4f6c698486b, topicName=甲状腺乳头状癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 27 21:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813496, encodeId=7f1b181349689, content=<a href='/topic/show?id=b887928146b' target=_blank style='color:#2F92EE;'>#超声特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92814, encryptionId=b887928146b, topicName=超声特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Aug 07 02:55:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044979, encodeId=924120449e925, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 25 08:55:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354964, encodeId=188f1354964a3, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363792, encodeId=02921363e92b6, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220474, encodeId=fbdf2204e435, content=谢谢分享,有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Mon Jul 10 00:50:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219946, encodeId=06a121994660, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jul 08 12:54:18 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2086217, encodeId=d714208621ef0, content=<a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18243, encryptionId=ed621824388, topicName=V600E突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 04 11:55:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798694, encodeId=1e241e986944a, content=<a href='/topic/show?id=4f6c698486b' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69848, encryptionId=4f6c698486b, topicName=甲状腺乳头状癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 27 21:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813496, encodeId=7f1b181349689, content=<a href='/topic/show?id=b887928146b' target=_blank style='color:#2F92EE;'>#超声特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92814, encryptionId=b887928146b, topicName=超声特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Aug 07 02:55:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044979, encodeId=924120449e925, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 25 08:55:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354964, encodeId=188f1354964a3, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363792, encodeId=02921363e92b6, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220474, encodeId=fbdf2204e435, content=谢谢分享,有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Mon Jul 10 00:50:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219946, encodeId=06a121994660, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jul 08 12:54:18 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
    2017-07-10 1de15b39m16(暂无匿称)

    谢谢分享,有新意

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2086217, encodeId=d714208621ef0, content=<a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18243, encryptionId=ed621824388, topicName=V600E突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Apr 04 11:55:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798694, encodeId=1e241e986944a, content=<a href='/topic/show?id=4f6c698486b' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69848, encryptionId=4f6c698486b, topicName=甲状腺乳头状癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 27 21:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813496, encodeId=7f1b181349689, content=<a href='/topic/show?id=b887928146b' target=_blank style='color:#2F92EE;'>#超声特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92814, encryptionId=b887928146b, topicName=超声特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Aug 07 02:55:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044979, encodeId=924120449e925, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 25 08:55:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354964, encodeId=188f1354964a3, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363792, encodeId=02921363e92b6, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Mon Jul 10 00:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220474, encodeId=fbdf2204e435, content=谢谢分享,有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2861672661, createdName=1de15b39m16(暂无匿称), createdTime=Mon Jul 10 00:50:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219946, encodeId=06a121994660, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jul 08 12:54:18 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
    2017-07-08 139****5926

    好好文章学习了

    0

相关资讯

Int J Cardiol:血色素沉着症患者心脏移植与心肝移植分析!

由此可见,HT和HLT是血色素沉着症患者可行的治疗方案。血色素沉着症患者相比于其它病因的患者,更为年轻以及会增加等待的死亡率。

Neurology:激素治疗降AD风险或取决于应用时机

  美国一项研究表明,激素治疗(HT)与阿尔茨海默病(AD)风险的相关性可能取决于应用时机。论文发表于《神经病学》[Neurology 2012,79(18):1846]杂志。   研究纳入1995~2006年间能提供确切绝经信息和HT应用情况的女性1768名。在随访期间共176例女性发生AD。利用考克斯(Cox)比例风险模型评估HT应用与AD的相关性。   结果为,在绝经5年内,应